TB vaccine development and the End TB Strategy: importance and current status.
about
Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosisA third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsSleeping Beauty and the Story of the Bacille Calmette-Guérin VaccineImmunological consequences of strain variation within the Mycobacterium tuberculosis complex.Resuscitation-promoting factors are important determinants of the pathophysiology in Mycobacterium tuberculosis infection.Identification of novel antigen candidates for a tuberculosis vaccine in the adult zebrafish (Danio rerio).Commentary: The Role of Neutrophils in the Induction of Specific Th1 and Th17 during Vaccination against Tuberculosis.Mycobacterium tuberculosis Complex Exhibits Lineage-Specific Variations Affecting Protein Ductility and Epitope Recognition.Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of three protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.Progress in biopharmaceutical development.Next-Generation Vaccines Based on Bacille Calmette-Guérin.A Multi-Compartment Hybrid Computational Model Predicts Key Roles for Dendritic Cells in Tuberculosis Infection.Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors.PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.Development of New Preventive and Therapeutic Vaccines for Tuberculosis.RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection.Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in TuberculosisImpact of effective contact rate and post treatment immune status on population tuberculosis infection and disease using a mathematical modelThe never-ending story of the fight against tuberculosis: from Koch's bacillus to global control programsBoosting effect of IL-7 in interferon gamma release assays to diagnose Mycobacterium tuberculosis infection
P2860
Q28077155-BCD37A97-82E0-4255-B712-A94F3E80F344Q33724960-EED27DAE-3142-4584-B95E-C1D4532C6528Q33809045-B55E8B6C-E85D-4BDE-9761-A9FEB0207D84Q37208406-DCC818CB-3516-445C-8A54-DFBA1B63DE0CQ37717814-31F804C4-665C-4CD0-94DF-7D3FF63C7F46Q38880052-0C878B41-A5F9-4A40-B24A-FBBE3A8CA213Q40120455-60D3E2D6-2A8F-443F-846D-13FDFBE33119Q40195641-DDEF420F-47D0-41A3-8FC3-60265F43DB37Q41089843-B78A4C76-F0E2-472F-94A9-CE5D873B2E79Q41995267-40CA21DD-92E9-4C8A-82D6-C28CBCB273FBQ48253463-BE083184-1CB2-40BE-8C49-1C56D9339AE4Q49829375-E4060557-8BB9-47AF-9A42-A401973898B3Q51574513-57FBB452-73E3-4795-A5D0-13E5EE26B597Q52563498-99AE5C18-927F-4263-90FB-5E76779731B7Q52648767-181DB92D-0A19-4700-ACB0-FD717B88BCA7Q55280574-A2182D5D-EC60-466E-92C6-4BB905C1264AQ55498821-8A45EBB9-58DE-4202-8761-C6B9FA3B429EQ55691134-3C2BF8B4-66B7-4CEB-9784-89EFBF039DA2Q56976379-649B5B90-F1F8-4F45-B8B3-7045A0426ED4Q57263232-8F50C673-79A7-4384-80EB-447A511846DBQ58548220-278B8452-66EC-42BA-B064-CC41A6746FFEQ58696258-F056566A-F383-4198-A25D-4C50C5EBABDF
P2860
TB vaccine development and the End TB Strategy: importance and current status.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
TB vaccine development and the End TB Strategy: importance and current status
@nl
TB vaccine development and the End TB Strategy: importance and current status.
@ast
TB vaccine development and the End TB Strategy: importance and current status.
@en
type
label
TB vaccine development and the End TB Strategy: importance and current status
@nl
TB vaccine development and the End TB Strategy: importance and current status.
@ast
TB vaccine development and the End TB Strategy: importance and current status.
@en
prefLabel
TB vaccine development and the End TB Strategy: importance and current status
@nl
TB vaccine development and the End TB Strategy: importance and current status.
@ast
TB vaccine development and the End TB Strategy: importance and current status.
@en
P2860
P921
P3181
P356
P1476
TB vaccine development and the End TB Strategy: importance and current status.
@en
P2093
Lewis Schrager
P2860
P304
P3181
P356
10.1093/TRSTMH/TRW016
P407
P577
2016-04-01T00:00:00Z